- Cambridge NeuroScience and The Gladstone Institute of CardiovascularDisease of the USA are to collaborate in the development of treatments for Alzheimer's disease. The venture will focus on drugs to inhibit a form a apolipoprotein E, which has been linked to the development of AD. As a result of the agreement, Cambridge NeuroScience has established a subsidiary, called Cambridge NeuroScience Partners, of which it owns 80%. The latter will provide $1.25 million in funds to the Institute over three years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze